KALA BIO, INC. Debt Securities, Available-for-sale, Amortized Cost
KALA BIO, INC. (KALA) had Debt Securities, Available-for-sale, Amortized Cost of $9.92 million as of 2023-06-30, per its 10-Q filed 2023-08-04.
Discontinued › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2023-08-04
- 2023-06-30: Debt Securities, Available-for-sale, Amortized Cost $9.92M.
- 2022-06-30: Debt Securities, Available-for-sale, Amortized Cost $2.00M.
- 2022-03-31: Debt Securities, Available-for-sale, Amortized Cost $4.99M.
- 2021-06-30: Debt Securities, Available-for-sale, Amortized Cost $5.00M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2023-06-30 | $9.92M 10-Q · filed 2023-08-04 |
| 2022-06-30 | $2.00M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $4.99M 10-Q · filed 2022-05-16 |
| 2021-06-30 | $5.00M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $28.01M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $76.27M 10-K · filed 2022-03-29 |
| 2020-09-30 | $113.60M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $56.55M 10-Q · filed 2020-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |